Company intelligence / Profile preview

ExoNavis Therapeutics

Tel Aviv, Tel Aviv District, Israel

Ownership: Private
Development stage: Other

Overview

ExoNavis is conducting a Phase 3 clinical trial (as of October 2024) of davunetide (NAP), an exosome-delivered neuroprotective peptide, for children with ADNP mutations, with prior clinical data indicating neuroprotective effects in related neurodegenerative and neurodevelopmental indications. The company holds FDA orphan drug and rare pediatric disease designation for ADNP syndrome[2][7][8].

Therapeutic areas: PsychiatryNeurology
Modalities: Exosome-based therapyPeptides
Industry: Biotech

Drug pipeline

1 asset

ProtEx

Preclinical

Beyond the preview

Go deeper on ExoNavis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoNavis Therapeutics.

Explore the full profile